NASDAQ:SAVACassava Sciences Stock Price, Forecast & News

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have decreased by 22.4% and is now trading at $3.29. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cassava Sciences.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cassava Sciences.

Cassava Sciences Inc (NASDAQ:SAVA) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.05) EPS for the quarter. View Cassava Sciences' earnings history.

Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

2 brokerages have issued 12-month price targets for Cassava Sciences' shares. Their forecasts range from $12.00 to $16.00. On average, they expect Cassava Sciences' stock price to reach $14.00 in the next year. This suggests a possible upside of 325.5% from the stock's current price. View analysts' price targets for Cassava Sciences.

Press coverage about SAVA stock has trended positive on Friday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cassava Sciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Cassava Sciences.

Some companies that are related to Cassava Sciences include Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Rigel Pharmaceuticals (RIGL), Bicycle Therapeutics (BCYC), Pivot Pharmaceuticals (PVOTF), Spero Therapeutics (SPRO), Avadel Pharmaceuticals (AVDL), Menlo Therapeutics (MNLO), IDEAYA Biosciences (IDYA), Abeona Therapeutics (ABEO), OrganiGram (OGI), AMAG Pharmaceuticals (AMAG), ProQR Therapeutics (PRQR), Northwest Biotherapeutics (NWBO) and MediciNova (MNOV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), DURECT (DRRX), Bristol-Myers Squibb (BMY), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Exelixis (EXEL), Novavax (NVAX) and Opko Health (OPK).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAVA stock can currently be purchased for approximately $3.29.

Cassava Sciences has a market capitalization of $81.53 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.

The official website for Cassava Sciences is www.cassavasciences.com.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]